A BILL 
To amend title XIX of the Social Security Act to promote 
access to life-saving therapies for Medicaid enrollees by 
ensuring coverage of routine patient costs for items and 
services furnished in connection with participation in 
qualifying clinical trials, and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Covering Life-saving 
4
Investigations Needed in Cancer and Other Life-threat-
5
ening Conditions through Timely use of Resources for 
6
Easy and Affordable Treatment from Medicaid for Enroll-
7
21:12 Feb 11, 2019
H913
2 
•HR 913 IH
ees in Need Today Act’’ or the ‘‘CLINICAL TREAT-
1
MENT Act’’. 
2
SEC. 2. PROMOTING ACCESS TO LIFE-SAVING THERAPIES 
3
FOR MEDICAID ENROLLEES BY ENSURING 
4
COVERAGE OF ROUTINE PATIENT COSTS FOR 
5
ITEMS AND SERVICES FURNISHED IN CON-
6
NECTION WITH PARTICIPATION IN QUALI-
7
FYING CLINICAL TRIALS. 
8
(a) IN GENERAL.—Section 1905 of the Social Secu-
9
rity Act (42 U.S.C. 1396d) is amended— 
10
(1) in subsection (a)— 
11
(A) in paragraph (29), by striking ‘‘and’’ 
12
at the end; 
13
(B) by redesignating paragraph (30) as 
14
paragraph (31); and 
15
(C) by inserting after paragraph (29) the 
16
following new paragraph: 
17
‘‘(30) subject to subsection (ff), routine patient 
18
costs for items and services furnished in connection 
19
with participation in a qualifying clinical trial (as 
20
defined in such subsection); and’’; and 
21
(2) by adding at the end the following new sub-
22
section: 
23
‘‘(ff)(1) ROUTINE PATIENT COSTS.—For purposes of 
24
subsection (a)(30), with respect to a State and an indi-
25
21:12 Feb 11, 2019
H913
3 
•HR 913 IH
vidual enrolled under the State plan (or a waiver of such 
1
plan) who participates in a qualifying clinical trial, routine 
2
patient costs— 
3
‘‘(A) include any item or service provided to the 
4
individual under the qualifying clinical trial, includ-
5
ing any item or service provided to prevent, diag-
6
nose, or treat complications resulting from such par-
7
ticipation, to the extent that the provision of such an 
8
item or service to the individual outside the course 
9
of such participation would otherwise be covered 
10
under the State plan (or waiver); and 
11
‘‘(B) does not include— 
12
‘‘(i) the investigational item or service that 
13
is the subject of the qualifying clinical trial; or 
14
‘‘(ii) an item or service that is provided to 
15
the individual solely to satisfy data collection 
16
and analysis needs for the qualifying clinical 
17
trial and is not used in the direct clinical man-
18
agement of the individual. 
19
‘‘(2) QUALIFYING CLINICAL TRIAL DEFINED.— 
20
‘‘(A) IN GENERAL.—For purposes of this sub-
21
section and subsection (a)(30), the term ‘qualifying 
22
clinical trial’ means a phase I, phase II, phase III, 
23
or phase IV clinical trial that is conducted in rela-
24
tion to the prevention, detection, or treatment of 
25
21:12 Feb 11, 2019
H913
4 
•HR 913 IH
cancer or any other life-threatening condition and is 
1
described in any of the following clauses: 
2
‘‘(i) The study or investigation is approved 
3
or funded (which may include funding through 
4
in-kind contributions) by one or more of the fol-
5
lowing: 
6
‘‘(I) 
The 
National 
Institutes 
of 
7
Health. 
8
‘‘(II) The Centers for Disease Control 
9
and Prevention. 
10
‘‘(III) The Agency for Healthcare Re-
11
search and Quality. 
12
‘‘(IV) The Centers for Medicare & 
13
Medicaid Services. 
14
‘‘(V) A cooperative group or center of 
15
any of the entities described in subclauses 
16
(I) through (IV) or the Department of De-
17
fense or the Department of Veterans Af-
18
fairs. 
19
‘‘(VI) A qualified non-governmental 
20
research entity identified in the guidelines 
21
issued by the National Institutes of Health 
22
for center support grants. 
23
21:12 Feb 11, 2019
H913
5 
•HR 913 IH
‘‘(VII) Any of the following if the con-
1
ditions described in subparagraph (B) are 
2
met: 
3
‘‘(aa) The Department of Vet-
4
erans Affairs. 
5
‘‘(bb) The Department of De-
6
fense. 
7
‘‘(cc) The Department of Energy. 
8
‘‘(ii) The clinical trial is conducted under 
9
an investigational new drug application re-
10
viewed by the Food and Drug Administration. 
11
‘‘(iii) The clinical trial is a drug trial that 
12
is exempt from having such an investigational 
13
new drug application. 
14
‘‘(B) CONDITIONS.—For purposes of subpara-
15
graph (A)(i)(VII), the conditions described in this 
16
subparagraph, with respect to a clinical trial ap-
17
proved or funded by an entity described in such sub-
18
paragraph (A)(i)(VII), are that the clinical trial has 
19
been reviewed and approved through a system of 
20
peer review that the Secretary determines— 
21
‘‘(i) to be comparable to the system of peer 
22
review of studies and investigations used by the 
23
National Institutes of Health; and 
24
21:12 Feb 11, 2019
H913
6 
•HR 913 IH
‘‘(ii) assures unbiased review of the highest 
1
scientific standards by qualified individuals with 
2
no interest in the outcome of the review. 
3
‘‘(3) LIFE-THREATENING CONDITION DEFINED.— 
4
For purposes of this subsection, the term ‘life-threatening 
5
condition’ means any disease or condition from which the 
6
likelihood of death is probable unless the course of the dis-
7
ease or condition is interrupted. 
8
‘‘(4) COVERAGE DETERMINATION REQUIREMENTS.— 
9
A determination with respect to coverage under subsection 
10
(a)(30) for an individual participating in a qualifying clin-
11
ical trial— 
12
‘‘(A) shall be expedited and completed within 
13
48 hours; 
14
‘‘(B) shall be made without limitation on the 
15
geographic location or network affiliation of the 
16
health care provider treating such individual or the 
17
principal investigator of the qualifying clinical trial; 
18
‘‘(C) shall be based solely on attestation regard-
19
ing the appropriateness of the qualifying clinical 
20
trial by the health care provider and principal inves-
21
tigator described in subparagraph (B), which shall 
22
be made using a streamlined, uniform form devel-
23
oped for national use by the Secretary and that in-
24
cludes the option to reference information regarding 
25
21:12 Feb 11, 2019
H913
7 
•HR 913 IH
the qualifying clinical trial that is publicly available 
1
on a website maintained by the Secretary, such as 
2
clinicaltrials.gov (or a successor website); and 
3
‘‘(D) shall not require submission of the proto-
4
cols of the qualifying clinical trial, or any other doc-
5
umentation that may be proprietary or determined 
6
by the Secretary to be burdensome to provide.’’. 
7
(b) REQUIRING
MANDATORY
COVERAGE
UNDER 
8
STATE PLAN.—Section 1902(a)(10)(A) of such Act is 
9
amended, in the matter preceding clause (i), by striking 
10
‘‘and (29)’’ and inserting ‘‘(29), and (30)’’. 
11
(c) ENSURING ACCESS FOR MEDICAID EXPANSION 
12
13
ed by inserting before the period at the end the following: 
14
‘‘, and beginning January 1, 2020, coverage of routine pa-
15
tient costs for items and services furnished in connection 
16
with participation in a qualifying clinical trial (as defined 
17
in section 1905(ff))’’. 
18
(d) EFFECTIVE DATE.— 
19
(1) IN GENERAL.—The amendments made by 
20
this section shall apply with respect to items and 
21
services furnished on or after the date of the enact-
22
ment of this Act. 
23
(2) EXCEPTION FOR STATE LEGISLATION.—In 
24
the case of a State plan under title XIX of the So-
25
21:12 Feb 11, 2019
H913
8 
•HR 913 IH
cial Security Act (42 U.S.C. 1396 et seq.) that the 
1
Secretary of Health and Human Services determines 
2
requires State legislation in order for the respective 
3
plan to meet any requirement imposed by amend-
4
ments made by this section, the respective plan shall 
5
not be regarded as failing to comply with the re-
6
quirements of such title solely on the basis of its 
7
failure to meet such an additional requirement be-
8
fore the first day of the first calendar quarter begin-
9
ning after the close of the first regular session of the 
10
State legislature that begins after the date of the en-
11
actment of this Act. For purposes of the previous 
12
sentence, in the case of a State that has a 2-year 
13
legislative session, each year of the session shall be 
14
considered to be a separate regular session of the 
15
State legislature. 
16
Æ 
21:12 Feb 11, 2019
H913
